CORRECTION article

Front. Pharmacol., 08 October 2024

Sec. Ethnopharmacology

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1488968

Corrigendum: Guanxin Danshen formulation protects against myocardial ischemia reperfusion injury-induced left ventricular remodeling by upregulating estrogen receptor β

  • 1. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • 2. Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China

  • 3. Key Laboratory of Efficacy Evaluation of Chinese Medicine against Glycerolipid Metabolism Disorder Disease, State Administration of Traditional Chinese Medicine, Beijing, China

  • 4. Zhongguancun Open Laboratory of the Research and Development of Natural Medicine and Health Products, Beijing, China

  • 5. Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Beijing, China

  • 6. Yunnan Branch, Institute of Medicinal Plant, Chinese Academy of Medical Sciences and Peking Union Medical College, Jinghong, China

In the published article, there was an error in Figure 4 as published. In Figure 4A, the “Sham” and “High dose” group inadvertently used the same representative images as those in Figure 3A. The corrected Figure 4 appears below.

FIGURE 4

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

Guanxin Danshen formula, myocardial ischemia reperfusion injury, ventricular remodeling, network pharmacology, estrogen receptor β, PI3K/Akt

Citation

Deng X, Xing X, Sun G, Xu X, Wu H, Li G and Sun X (2024) Corrigendum: Guanxin Danshen formulation protects against myocardial ischemia reperfusion injury-induced left ventricular remodeling by upregulating estrogen receptor β. Front. Pharmacol. 15:1488968. doi: 10.3389/fphar.2024.1488968

Received

31 August 2024

Accepted

23 September 2024

Published

08 October 2024

Volume

15 - 2024

Edited and reviewed by

Michael Heinrich, University College London, United Kingdom

Updates

Copyright

*Correspondence: Guibo Sun, ; Xiaobo Sun,

† These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics